Soliqua is lixisenatide and insulin glargine.
Repurposed for investigation into the treatment of Parkinson's disease.
- TRADE NAMES: Adlyxin (Sanofi-Aventis); Lyxumia (Sanofi-Aventis); Soliqua (Sanofi-Aventis)
- INDICATIONS: To improve glycemic control in adults with Type II diabetes mellitus
- CLASS: Antidiabetic, Glucagon-like peptide-1 (GLP-1) receptor agonist (incretin mimetic), Incretin mimetic (see also Glucagon-like peptide-1 (GLP-1) receptor agonist)
- HALF-LIFE: 3 hours
- FDA APPROVAL DATE: 07/27/2016
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: Use during pregnancy only if the potential benefit justifies the potential risk to the fetus
- See adverse reactions attributed to class:
Glucagon-like peptide-1 (GLP-1) receptor agonist (incretin mimetic)
Please login to view the rest of this drug profile.
Page last updated 06/09/2026
